Cell therapy promotes axon remyelination in a mouse model
News Aug 18, 2016
Demyelinating diseases, such as multiple sclerosis and leukodystrophy, are characterized by damage to the protective myelin sheath that surrounds the axons of neurons. This demyelination can be caused by an autoimmune response or impaired myelin production by oligodendrocytes.
See Also: Researchers present new view of myelin
A new report in JCI Insight from Arjun Saha and colleagues at Duke University demonstrates that a cell therapy product called DUOC-01 can accelerate remyelination of axons in mice treated with a demyelinating chemical agent.
DUOC-01 cells, which are derived from banked umbilical cord blood, were transplanted into mice following toxic demyelination. DUOC-01 treatment resulted in faster remyelination and promoted the differentiation of oligodendrocyte progenitor cells.
These results suggest that a cord blood-derived cell product can promote neuronal repair and remyelination. Future clinical studies will be needed to determine if DUOC-01 cell therapy benefits patients with demyelinating diseases.
Note: Material may have been edited for length and content. For further information, please contact the cited source.
Saha A et al. A cord blood monocyte–derived cell therapy product accelerates brain remyelination. JCI Insight, Published Online August 18 2016. doi: 10.1172/jci.insight.86667
Adult depression has long been associated with shrinkage of the hippocampus, a brain region that plays an important role in memory and response to stress. Now, new research has linked participation in team sports to larger hippocampal volumes in children and less depression in boys ages 9 to 11.
Researchers have discovered a brain process common to sleep and ageing in research that could pave the way for new treatments for insomnia. The scientists report how oxidative stress leads to sleep. Oxidative stress is also believed to be a reason why we age and a cause of degenerative diseases.READ MORE
Patients in a new Northwestern Medicine study were able to comprehend words that were written but not said aloud. They could write the names of things they saw but not verbalize them. This provides an insight into the brain degeneration that defines the rare dementia termed primary progressive aphasia.